News

Exciting Updates from Kura Oncology on Investor Engagements

Exciting Updates from Kura Oncology on Investor Engagements

Kura Oncology Engages Investors with Upcoming Conferences

Kura Oncology, Inc. (KURA), a pioneering biopharmaceutical company, is making significant strides in the realm of cancer treatment. The company is set to partake in three notable investor conferences, showcasing its commitment to precision medicine and innovative therapies.

Upcoming Investor Conferences

Troy Wilson, Ph.D., J.D., Kura's President and Chief Executive Officer, will lead discussions and share insights regarding Kura's advancements in cancer treatment. Here's a look at the three important conferences where Kura will be prominently featured:

TD Cowen Health Care Conference

The first event is the TD Cowen Health Care Conference. Taking place in Boston, it will feature a fireside chat where Dr. Wilson is expected to discuss Kura's ongoing projects and future plans. This chat is scheduled for 2:30 p.m. ET / 11:30 a.m. PT on an upcoming date.

Barclays Global Healthcare Conference

Next, Kura will participate in the Barclays Global Healthcare Conference in Miami. Dr. Wilson will engage with attendees at a fireside chat scheduled for 9:30 a.m. ET / 6:30 a.m. PT on another specified date. The conversations here will be vital in sharing Kura's vision for cancer treatments.

Leerink Partners Global Biopharma Conference

Finally, the Leerink Partners Global Biopharma Conference, also in Miami, will feature Dr. Wilson at a fireside chat at 8:00 a.m. ET / 5:00 a.m. PT. This gathering will further bolster Kura's outreach to investors and stakeholders.

Webcasts for Investor Engagement

For those unable to attend in person, Kura will offer live audio webcasts of all investor presentations. These webcasts can be accessed in the Investors section of Kura's official website, ensuring that a broader audience can stay informed about the company's developments. Archived replays will also be available for later viewing.

About Kura Oncology

Kura Oncology is dedicated to transforming cancer care through its innovative approaches. At the heart of their pipeline is ziftomenib, an oral menin inhibitor recognized for its potential in treating relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). It holds the distinction of being the first investigational medicine to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA).

Strategic Collaborations and Clinical Trials

In a noteworthy development, Kura Oncology entered into a strategic collaboration with Kyowa Kirin Co., Ltd., aimed at furthering the research and commercialization of ziftomenib, particularly focusing on AML and similar hematologic disorders. The company has recently completed enrollment for a Phase 2 trial targeting relapsed/refractory NPM1-mutant AML.

Additional Drug Development

In addition to ziftomenib, Kura is exploring other promising candidates. KO-2806, a next-generation farnesyl transferase inhibitor, is currently in a Phase 1 dose-escalation trial, being evaluated both alone and in combination with other targeted therapies.

Further Information

For more details about Kura Oncology’s initiatives and developments, interested parties can visit Kura's website or follow the company on various social media platforms, including LinkedIn and X. This engagement is part of Kura's broader commitment to transparency and investor relations.

Frequently Asked Questions

What is Kura Oncology's primary focus?

Kura Oncology focuses on developing precision medicines for treating cancer.

Who will represent Kura at the investor conferences?

Troy Wilson, Ph.D., J.D., the President and CEO, will represent Kura Oncology.

Where can I access the webcasts for these conferences?

The webcasts will be available on Kura's official website in the Investors section.

What notable drug is Kura Oncology developing?

Kura is developing ziftomenib, an oral menin inhibitor for treating AML.

Has Kura partnered with other organizations?

Yes, Kura has a collaboration agreement with Kyowa Kirin to enhance its drug development efforts.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 157

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 70

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 192

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 147

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Analysis of Strategy Inc's Recent Stock Performance

Updated Category News Views 143

Strategy Inc (NASDAQ: MSTR) Faces Critical Trading Challenges Strategy Inc stock recently closed at $300.70, marking a notable decline of approximately 7%. This downturn has positioned the stock at a pivotal moment in its trading journey, stirring discussions among analysts and investors alike. Technical Analysis Reveals Breakdown Risks Following a series of downward...

Continue Reading
Major Bank Stock Opportunities Following Fed's Rate Reductions

Updated Category News Views 77

Major Bank Stock Opportunities Following Fed's Rate Reductions The recent cut in interest rates by the Federal Reserve marks a crucial shift in the banking industry, especially for mid- and small-cap banks. With a reduction of 50 basis points, this decision indicates a new phase that could improve profitability across the banking sector. Analyst Steven Alexopoulos at...

Continue Reading
SafeRent Resolves Discrimination Lawsuit with $2.3M Settlement

Updated Category News Views 519

SafeRent Settles Discrimination Lawsuit for $2.3 Million SafeRent Solutions, a leading AI-driven tenant screening service, has successfully settled a class action lawsuit aimed at its screening practices. The case, filed in a Massachusetts court, raised significant concerns regarding the treatment of low-income renters. Details of the Settlement Recently, U.S. District...

Continue Reading
Medical Experts Rally Behind RFK Jr. for HHS Leadership

Updated Category News Views 496

Support from Medical Professionals for RFK Jr. Leadership In a compelling demonstration of support, more than 800 medical professionals have signed a letter endorsing Robert F. Kennedy Jr. for the position of Secretary of Health and Human Services (HHS). This unified action showcases the broad consensus among healthcare leaders that significant reforms are essential to...

Continue Reading
Lundin Gold's Exploration Uncovers Exceptional Porphyry Grades

Updated Category News Views 169

Exciting Developments in Exploration for Lundin Gold Lundin Gold Inc. (TSX: LUG) has made remarkable progress in its exploration activities at the Fruta del Norte (FDN) gold mine, revealing outstanding porphyry mineralization that showcases significant copper and gold potential. The mining company is currently focusing its efforts on three areas of interest: Sandia,...

Continue Reading